# FDA Approves TAUKLARIFY Tau PET Imaging Agent > The radioactive tracer can help estimate aggregated tau tangles in adults being evaluated for Alzheimer's disease, but the scan is neither a treatment nor a standalone diagnosis. _Source: Lantheus official announcement and prescribing information, with Reuters and Pharmacy Times independent reporting · 2026-08-15 · 6 min read · Verified against primary sources_ Canonical: https://iyu.app/e/tauklarify-tau-pet-fda-approval ## The 60-second version TAUKLARIFY is an FDA-approved intravenous radioactive tracer for brain PET imaging of aggregated tau tangles in certain adults undergoing evaluation for Alzheimer's disease. **Key points** - The scan estimates the density and distribution of aggregated tau neurofibrillary tangles. - It is intended for adults with cognitive impairment being evaluated for Alzheimer's disease, not general population screening. - The result is one component of a broader clinical assessment and cannot diagnose Alzheimer's disease by itself. - The procedure involves ionizing radiation, trained interpretation, and the technical limitations described in the prescribing information. **Verdict.** The approval adds a clinically useful tau-imaging option, but it is a diagnostic aid with radiation and interpretation limits, not treatment or a standalone answer. ## Full explainer The FDA has approved **TAUKLARIFY (florquinitau F 18 injection)**, an intravenous radioactive diagnostic agent for PET imaging of the brain. It is indicated to estimate the density and distribution of aggregated tau neurofibrillary tangles in adults with cognitive impairment who are being evaluated for Alzheimer's disease. > **⚑ Caveat:** TAUKLARIFY is not a treatment and a PET result is not a standalone Alzheimer's diagnosis. The image must be interpreted within a broader clinical evaluation. ### Regulatory action — What the FDA approved The approval covers a diagnostic use in a defined population: adults who already have cognitive impairment and are being evaluated for Alzheimer's disease. The tracer is given intravenously before PET imaging so clinicians can assess the pattern of aggregated tau tangles in the brain. - **Product:** TAUKLARIFY (florquinitau F 18 injection) - **Modality:** Brain positron emission tomography imaging - **Indicated population:** Adults with cognitive impairment being evaluated for Alzheimer's disease - **Information provided:** An estimate of the density and distribution of aggregated tau neurofibrillary tangles ### Biological signal — What tau PET adds Abnormal tau can accumulate inside neurons as neurofibrillary tangles. TAUKLARIFY is designed to produce a PET signal associated with aggregated tau, allowing a trained reader to evaluate where that signal is distributed and how extensive it appears. > The scan contributes evidence about tau pathology; it does not convert a complex clinical evaluation into a single yes-or-no answer. ### Clinical boundary — What the result cannot establish alone - It does not independently diagnose Alzheimer's disease or identify every possible cause of cognitive impairment. - It does not predict an individual's future rate of cognitive decline. - It does not determine automatically whether a particular treatment is appropriate or will work. - It is not a therapy and does not remove tau or improve symptoms. Clinicians must integrate the image with history, cognitive testing, examination, laboratory findings, other imaging, and the patient's circumstances. The approved indication should not be expanded casually to screening or uses outside the prescribing information. ### Safety — Radiation exposure requires clinical justification Florquinitau F 18 is radioactive, so the examination exposes the patient to ionizing radiation. Ordering, preparation, administration, imaging, and disposal should follow the prescribing information and institutional radiation-safety procedures. > **i** The relevant benefit-risk decision is whether the expected diagnostic information justifies a radiopharmaceutical PET examination for this patient, not whether the tracer is generally useful in the abstract. ### Interpretation — The reader and image quality remain part of the test A PET image is produced by the tracer, scanner, acquisition and processing methods, patient anatomy, and reader judgment. The label's interpretation method and reader training matter, and misleading positive or negative interpretations remain possible. ### Bottom line — A new tool, not a final verdict TAUKLARIFY expands the FDA-approved imaging options available to specialists evaluating certain adults with cognitive impairment. Its proper role is to add a tau-pathology signal to a complete assessment while preserving the limits of radiation-based imaging and clinical interpretation. ## Primary sources - [Lantheus — FDA approval announcement for TAUKLARIFY](https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-fda-approval-tauklarifytm-florquinitau-f-18) - [Lantheus — TAUKLARIFY Prescribing Information](https://www.lantheus.com/assets/TAUKLARIFY-Prescribing-Information.pdf) - [Reuters — US FDA approves Lantheus Alzheimer's diagnostic agent](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-lantheus-alzheimers-diagnostic-agent-2026-08-14/) - [Pharmacy Times — FDA approves TAUKLARIFY for tau pathology imaging](https://www.pharmacytimes.com/view/fda-approves-tauklarify-to-identify-tau-pathology-in-patients-being-evaluated-for-alzheimer-disease) --- _Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._